<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098488</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01460</org_study_id>
    <secondary_id>OSU 0429</secondary_id>
    <secondary_id>2004C0058</secondary_id>
    <secondary_id>NCI-6518</secondary_id>
    <secondary_id>OSU-0429</secondary_id>
    <secondary_id>CDR0000401516</secondary_id>
    <secondary_id>R21CA115048</secondary_id>
    <nct_id>NCT00098488</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia</brief_title>
  <official_title>A Phase 1 Study of 17-allylamino-17-demethoxygeldanamycin (17-AAG) (NSC 330507; IND 57,966) and Rituximab in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin when given with or without rituximab in treating&#xD;
      patients with relapsed B-cell chronic lymphocytic leukemia or prolymphocytic leukemia. Drugs&#xD;
      used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others&#xD;
      interfere with the ability of cancer cells to grow and spread. Monoclonal antibodies may kill&#xD;
      cancer cells that are left after chemotherapy. Giving&#xD;
      17-N-allylamino-17-demethoxygeldanamycin with or without rituximab may kill more cancer&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of twice weekly&#xD;
      17-allylamino-17-demethoxygeldanamycin (17-AAG) in combination with weekly rituximab in&#xD;
      patients with relapsed chronic lymphocytic leukemia (CLL).&#xD;
&#xD;
      II. To examine the pharmacology of twice weekly 17-AAG in combination with weekly rituximab&#xD;
      in patients with relapsed CLL.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate toxicity (using NCI CTCAE v3.0 criteria) and preliminary efficacy of twice&#xD;
      weekly 17-AAG when used in combination with weekly rituximab in this patient population.&#xD;
&#xD;
      II. To examine the kinetics of depletion of PDK1/AKT-related proteins, mutant p53 and&#xD;
      up-regulation of alternative targets that mediate resistance to therapy following treatment&#xD;
      with twice weekly 17-AAG; and the relationship of this to spontaneous and drug-induced&#xD;
      apoptosis in patients with relapsed CLL.&#xD;
&#xD;
      III. To examine the immunologic effects of twice weekly 17-AAG, in conjunction with weekly&#xD;
      rituximab, in patients with relapsed CLL.&#xD;
&#xD;
      IV. To evaluate toxicity and preliminary efficacy of twice weekly 17-AAG as a single agent in&#xD;
      this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin (17-AAG).&#xD;
&#xD;
      Patients receive 17-AAG intravenously (IV) over 2 hours on days 1, 4, 8, 11, 15 and 18&#xD;
      (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive&#xD;
      an additional course of single-agent 17-AAG approximately 10 days later in the absence of&#xD;
      disease progression or unacceptable toxicity and provided absolute lymphocyte count continues&#xD;
      to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1&#xD;
      OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to&#xD;
      combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22;&#xD;
      and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 17-AAG as a single agent or in&#xD;
      combination with rituximab until the maximum tolerated dose (MTD) is determined. The MTD is&#xD;
      defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience&#xD;
      dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed up at 2 months and then every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)</measure>
    <time_frame>Week 4</time_frame>
    <description>Defined at the dose level of 17-AAG at which 2 (or more) of 6 patients develop dose-limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimally effective pharmacological dose (MEPD) of 17-AAG based on down-modulation of the target protein Akt</measure>
    <time_frame>Day 1</time_frame>
    <description>Defined as the 17-AAG dose achieving &gt;= 50% reduction in Akt protein expression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (17-AGG and rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (17-AGG and rituximab)</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (17-AGG and rituximab)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed B-cell chronic lymphocytic leukemia or prolymphocytic&#xD;
             leukemia requiring treatment, defined by 1 of the following criteria:&#xD;
&#xD;
               -  Massive or progressive splenomegaly and/or lymphadenopathy&#xD;
&#xD;
               -  Anemia (hemoglobin &lt; 11 g/dL) OR thrombocytopenia (platelet count &lt; 100,000/mm^3)&#xD;
&#xD;
               -  Weight loss &gt; 10% within the past 6 months&#xD;
&#xD;
               -  Grade 2 or 3 fatigue&#xD;
&#xD;
               -  Fevers &gt; 100.5°F or night sweats for &gt; 2 weeks with no evidence of infection&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of &gt; 50% over a 2 month period OR an&#xD;
                  anticipated doubling time of &lt; 6 months&#xD;
&#xD;
          -  Relapsed disease&#xD;
&#xD;
          -  Failed prior fludarabine or pentostatin therapy OR cannot receive fludarabine&#xD;
&#xD;
          -  Lymphocyte count ≥ 5,000/mm^3&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  QTc &lt; 450 msec for male patients and &lt; 470 msec for female patients&#xD;
&#xD;
          -  Resting ejection fraction ≥ 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No significant cardiac disease including any of the following:&#xD;
&#xD;
               -  New York Heart Association class III or IV heart failure&#xD;
&#xD;
               -  History of myocardial infarction within the past year&#xD;
&#xD;
               -  History of uncontrolled dysrhythmias&#xD;
&#xD;
               -  Active ischemic heart disease within the past year&#xD;
&#xD;
               -  Poorly controlled angina&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (e.g., ventricular fibrillation, history&#xD;
             of symptomatic or sustained ventricular tachycardia, nonsustained ventricular&#xD;
             tachycardia &gt; 3 beats within the past 6 months)&#xD;
&#xD;
          -  No history of cardiac toxicity due to anthracyclines (e.g., doxorubicin hydrochloride,&#xD;
             daunorubicin hydrochloride, or mitoxantrone hydrochloride)&#xD;
&#xD;
          -  No other cardiac symptoms ≥ grade 2&#xD;
&#xD;
          -  DLCO (i.e., oxygen diffusion capacity) ≥ 80% by pulmonary function testing&#xD;
&#xD;
          -  Resting and exercise oxygen saturation ≥ 90% by pulse oximetry&#xD;
&#xD;
          -  No pulmonary symptoms ≥ grade 2&#xD;
&#xD;
          -  No history of pulmonary toxicity due to bleomycin or carmustine&#xD;
&#xD;
          -  No significant, symptomatic pulmonary disease requiring oxygen or medications&#xD;
&#xD;
          -  No ongoing pulmonary symptoms ≥ grade 2 including any of the following:&#xD;
&#xD;
               -  Dyspnea on or off exertion&#xD;
&#xD;
               -  Paroxysmal nocturnal dyspnea&#xD;
&#xD;
               -  Significant pulmonary disease (e.g., chronic obstructive or restrictive pulmonary&#xD;
                  disease)&#xD;
&#xD;
          -  No Medicare requirements for home oxygen (e.g., resting O_2 saturations ≥ 90% or&#xD;
             desaturation to ≥ 90% with exertion)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to 17-N-allylamino-17-demethoxygeldanamycin&#xD;
&#xD;
          -  No history of serious allergic reaction to eggs&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  More than 3 months since prior rituximab and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy that potentially included the heart in the field (e.g., mantle)&#xD;
&#xD;
          -  No history of chest radiation&#xD;
&#xD;
          -  No concurrent medications that prolong or may prolong QTc&#xD;
&#xD;
          -  No concurrent antiarrhythmic drugs&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

